Structured settlement is an agreement of payment towards compensation to an injured or disabled person out of asbestos exposure and the company that is responsible for this disability. Many countries banned asbestos related activities but the settlement cases still exists in various courts. They will exist for many more years. The reason is the symptoms of the disease called mesothelioma or asbestos cancer will be seen only after many years of exposure and the seriousness of the disease will be felt only at an advanced stage. The diseased will be losing his job and livelihood and the company causing this personal injury is bound to pay a very high penalty.

The disabled who claims for compensation must know the following points well before approaching the justice. The value of the compensation depends on

1. Age and earning capacity
2. How many asbestos containing products the plaintiff is exposed
3. The number of identifiable dependents existing Continue reading ‘Structured Settlements and Mesothelioma Cancer’ »

Mesothelioma cancer is a rare cancer that is thougth to come from the inhalation of asbestos fibers as well as exposure to asbestos. People that have work concerning plentiful amounts of asbestos are in danger of contracting mesothelioma. Studies have reasonably shown that the vast majority of those that have mesothelioma had exposure to asbestos at some point in the past whether it was work-related or otherwise.

Mesothelioma is also a relatively rare form of cancer with only about 4000 cases each year. The three major varieties of mesothelioma all match up to the area of the mesothelium that is affected. They are known as Pericardial, Peritoneal and Pleural Mesothelioma.

The cancer is named after the mesothelium, which is a protective membrane that covers various cavities. Peritoneal, Pleural and Peritoneal mesothelioma are all named after the particular cavities that this cancer affects. The symptoms for each are different. Continue reading ‘Mesothelioma – What is Mesothelioma Cancer?’ »

The kind of mesothelioma that is found in the peritonium region is named peritoneal mesothelioma. The peritonium is a membrane that lines the abdominal region of our body. Peritoneal mesothelioma represents a small number of all mesothelioma cases at about 30%. Patients that suffer from peritoneal mesothelioma are commonly found to have been exposed to asbestos over a period of time in the past.

The duration of exposure necessary needed for peritoneal mesothelioma to result is unknown. Abdominal pain, swelling and lumps in the abdominal as well as anemia are just a quantity of of the symptoms of this kind of cancer. Almost all patients suffering from peritoneal mesothelioma will lose their lives to it in the end.

A cure has not been found and efforts are regularly made in the region of lengthening life expectancy. The way asbestos affects the peritonium is how the cells of the membrane react to the fibers themselves. The cells begin to divide at a very high rate causing the membrane to thicken. Continue reading ‘Information On Peritoneal Mesothelioma’ »

Mesothelioma cancer that affects the pleura is called pleural mesothelioma. The pleura is the membrane responsible for holding the walls of our chest and our lungs. About 40 percent of all instances are pericardial and peritoneal, the remaining bulk is made up of pleural mesothelioma.

When cancer affects the lung lining, it is called pleural mesothelioma. It is thought that asbestos exposure is the main cause of all kinds of mesothelioma.

Those who smoke and work around asbestos without suitable protection stand a bigger probability of getting mesothelioma. Lumps around the chest area as well as chest pains could be symptoms of pleural mesothelioma. Breathing might be impaired and even painful. Continue reading ‘Pleural Mesothelioma – What Is It?’ »

Most mesothelioma doctors work at hospitals that are good at cancer care. Mesothelioma cancer is best treated at large cancer centers which have the needed experience in mesothelioma treatment. If you live in a small town, you may need to travel to a larger city to find a center with enough mesothelioma cancer experience. This experience advantage may be the key to getting the best possible treatment and be well worth any extra travel or inconvenience to you in the short-term.

These are some steps you should take to look for the best treatment center:

1-Ask other doctors and nurses for their opinions on hospitals in your area. Your primary doctor who was the first doctor to suspect that you have this type of cancer is the first person you should ask to suggest the names of 2 -3 good mesothelioma doctors and the hospitals where they are currently practicing to you.

2-You can also seek for information from an organization called The Joint Commission. This organization accredits hospitals that meet their very stringent although not all the hospitals they accredit are expert in cancer treatment. Continue reading ‘Mesothelioma Treatment Centers- How to Find the Best One For You’ »

To understand the application of the treatment of cancer with flax seed oil is to understand the performance of human organs in cellular repair.

This basis is used by a German scientist named Dr. Johanna Budwig, a method that he uses is to restore the balance of essential nutrients, so as to create a balance of work of the organs. The fact that the hemoglobin content of the blood of people who suffer from cancer and other degenerative diseases are very less. But the blood of healthy people have sufficient quantities. This is also the basis of the theory that patients with cancer and degenerative diseases tend to suffer from anemia.

By combining natural and formulate a recipe that has been developed Dr.Budwig proven cancer patients after undergoing therapy flax seed oil for three months of cancer cells will be replaced with a cell body that is more alive and healthy. Continue reading ‘Alternative Cancer Treatments – Flax Seed Oil’ »

“Cancer” is a scary word, but a diagnosis of mesothelioma cancer is particularly difficult because the disease is considered incurable. What’s worse, many people suffering from mesothelioma were exposed to the substance that can cause it – asbestos – on the job. And in many cases, companies knew about the dangers of asbestos and did nothing to warn workers.

What Did They Know?

Asbestos is a silicate mineral used in manufacturing due to its strength and resistance to heat and fire. When inhaled, asbestos fibers can get inside the membrane that lines the lung cavity, among other tissues. This can cause cells to divide abnormally, and the result is cancer. Another complication from asbestos exposure is asbestosis, which results when the lungs have become scarred from the inhalation of asbestos, resulting in breathing difficulties. The effects of asbestos exposure can’t be reversed; symptoms can only be managed. Continue reading ‘Holding Manufacturers Financially Liable for Mesothelioma’ »

Another interesting study is called, “Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B” – Clinical Cancer Research March 2005 11; 2300 by Ramaswamy Govindan, Robert A. Kratzke, James E. Herndon II, Gloria A. Niehans, Robin Vollmer, Dorothy Watson, Mark R. Green, Hedy L. Kindler and on behalf of the Cancer and Leukemia Group B. Here is an excerpt: “Abstract – Purpose: The Cancer and Leukemia Group B conducted a phase II study of gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, in patients with previously untreated malignant mesothelioma. Experimental Design: Eligible patients had unresectable pleural or peritoneal mesothelioma, measurable disease, no prior therapy, and performance status 0-1 by Cancer and Leukemia Group B criteria. Gefitinib (500 mg p.o.) was administered once a day for 21 days. Patients underwent restaging after every two cycles. Therapy was continued until disease progression or unacceptable toxicity. Results: The most common grade 3 toxicities were diarrhea (16%) and nausea (12%). Of 43 patients enrolled, 1 patient (2%) had a complete response, 1 patient (2%) had a partial response, 21 (49%) had stable disease lasting two to eight cycles, 15 (35%) had progressive disease, and 5 (12%) had early deaths. One-year survival was 32% [95% confidence interval (CI), 21-50%]. Median survival and failure-free survival were 6.8% (95% CI, 3.5-10.3) and 2.6 months (95% CI, 1.5-4.0), respectively. The 3-month failure-free survival was 40% (95% CI, 25-56%). EGFR expression score by immunohistochemistry done in 28 patients was categorized as low (EGFR 1+ or 2+) or high (EGFR 3+) expression: 97% had EGFR over[removed]2+ or 3+). The median and 3-month failure-free survival were 3.6 months and 40% for those patients with low EGFR expression compared with 8.1 and 40% for those with high EGFR expression.” Continue reading ‘Unresectable Pleural and Peritoneal Mesothelioma Research’ »

An interesting study is called, “Aggressive multimodality therapy for malignant pleural Mesothelioma” – The Annals of Thoracic Surgery – Volume 58, Issue 1, July 1994, Pages 24-29 by Thomas W. Rice MD, David J. Adelstein MD, Thomas J. Kirby MD, Matthew G. Saltarelli MD, Siva R. Murthy MD, Marjorie A. Van Kirk RN, Herbert P. Wiedemann MD and James K. Weick MD – Here is an excerpt: “Abstract – Nineteen patients with clinical stage I malignant pleural mesothelioma were treated with aggressive multimodality therapy. Nine patients underwent pleurectomy and decortication followed by immediate intrapleural chemotherapy with cisplatin and mitomycin C. Ten patients required pleuropneumonectomy followed within 1 week to 2 weeks by intrapleural administration of cisplatin (100 mg). Four to 8 weeks after operation, 15 patients underwent postoperative adjuvant cisplatin-based systemic chemotherapy. There were three postoperative complications (16%) requiring reoperation and one postoperative death (5%). Intrapleural chemotherapy was well tolerated with no complications. Systemic chemotherapy was poorly tolerated, and there was one chemotherapy-related death. Sixteen patients (84%) experienced good to excellent palliation. Three patients are currently alive with no evidence of recurrent disease at 10, 35, and 43 months. The median overall survival was 13 months and the median disease-free survival, 11 months. Overall and disease-free 3 year survivals were 17% and 22%, respectively. Patients with epithelial malignant pleural mesothelioma had significantly better overall survival (p = 0.037) and disease-free survival (p = 0.02) than patients with sarcomatous or biphasic malignant pleural mesothelioma. We conclude that despite major toxicity, in select patients with clinical stage I malignant pleural mesothelioma, aggressive multimodality therapy offers effective palliation and occasional long-term disease-free survival.” Continue reading ‘Pleurectomy and Decortication Followed by Immediate Intrapleural Chemotherapy’ »

Another interesting study is called, “Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.” By Ordóñez NG. The University of Texas M.D. Anderson Cancer Center, Houston 77030 – Mod Pathol. 1998 Oct;11(10):929-33.  Here is an excerpt: “Abstract – Only recently have immunohistochemical markers been recognized that are commonly expressed in epithelial mesotheliomas but not in adenocarcinomas. Among these, calretinin generated a great deal of interest, but the number of studies evaluating the practical use of calretinin immunostaining in the diagnosis of mesothelioma is limited, and the study results are controversial. To evaluate whether calretinin immunostaining can assist in distinguishing between epithelial pleural mesothelioma and lung adenocarcinoma and other carcinomas metastatic to the pleura, 38 pulmonary adenocarcinomas, 117 nonpulmonary adenocarcinomas, 28 squamous cell carcinomas of the lung, 8 large-cell undifferentiated carcinomas of the lung, and 9 transitional cell carcinomas metastatic to the lung were studied. Reactivity was observed in all of the 38 mesotheliomas, whereas only 3 of the 38 pulmonary adenocarcinomas and 11 of the 117 nonpulmonary adenocarcinomas (5/38 ovarian, 2/15 endometrial, 2/23 breast, 2/16 colonic, 0/8 kidney, 0/8 prostatic, 0/6 thyroid, and 0/3 pancreatic) exhibited weak or focal staining. Eleven of the 28 squamous carcinomas of the lung were also positive. No reactivity was observed in any of the large cell undifferentiated carcinomas of the lung or in the transitional cell carcinomas. It is concluded that calretinin immunostaining is not only helpful in discriminating epithelial pleural mesotheliomas from pulmonary adenocarcinomas but that it can also assist in distinguishing epithelial mesotheliomas from nonpulmonary adenocarcinomas metastatic to the pleura.” Continue reading ‘Mesothelioma and the Potential Accessibility of Tumors’ »